BioProtect Overview
BioProtect has developed a proprietary technology platform for biodegradable balloons. The technology is designed for a wide range of clinical applications, including spacing for radiation oncology protection, aesthetics, and general surgery. The company's first application in the commercialization stage is the BioProtect/ProSpace Balloon System, which acts as a spacer for the protection of healthy tissue in patients receiving radiotherapy for prostate cancer. The product is commercially available in Europe and is undergoing clinical studies in the United States prior to FDA approval. BioProtect has a robust product pipeline developed in consultation with physicians regarding radiotherapy spacing and other unmet clinical needs.
Cumulative Funding Raised Over Time ($)
$4.0MApr 2017
$6.9MDec 2012
$7.6MFeb 2006
$8.6MJun 2008
$9.1MJun 2016
$9.1MMay 2025
$9.2MOct 2004
$34.2MSep 2020
$62.2MSep 2023
Latest News
growth-positive
Israeli balloon implant co BioProtect raises $28m
Israeli balloon implant company BioProtect has completed a $28 million financing round led by MVM Partners, with participation from current investors. The funds will be used for US commercialization of the BioProtect Balloon Implant System, which recently received FDA clearance for rectal protection during radiation therapy for prostate cancer. The companys CEO, Itay Barnea, expressed his belief in the potential of their product to revolutionize rectal protection from radiation toxicity during prostate cancer radiation therapy.
InvestmentExpand
growth-positive
Is it time to reconsider PSA tests for Prostate Cancer? | CTech
The article discusses the debate surrounding prostate cancer screening and treatment. It highlights the importance of personalized, patient-centered approaches and the potential side effects of invasive treatments. The CEO of BioProtect, Itay Barnea, emphasizes the need for a comprehensive evaluation of each patients unique factors. The global market for prostate cancer therapeutics is predicted to exceed $24.9 billion by 2030, driven by increasing cases and technological advancements in oncology. BioProtect produces biodegradable balloons for safe radiation therapy.
CustomersInvestment
growth-positive
BioProtect Notes Completion of Patient Enrollment for its IDE Pivotal Study of the ProSpace™ Balloon Spacer
BioProtect Ltd. has successfully enrolled all planned patients in the ongoing IDE ProSpace™ trial for its ProSpace™ Balloon Spacer. The trial aims to assess the safety and efficacy of the device in prostate cancer patients undergoing radiotherapy. The company expressed gratitude for the completion of the enrollment phase despite the challenges posed by the COVID-19 pandemic. BioProtects vision is to provide safer and improved clinical outcomes for patients undergoing radiation therapy. Last year, the company raised $25 million in funding from a group of international investors. The ProSpace™ Balloon Spacer is BioProtects first commercially available product, designed to reduce the radiation dose delivered to the anterior rectum by spacing it away from the prostate.
Investment
growth-positive
Prostate cancer protection co BioProtect raises $25m
Israeli startup BioProtect has closed a $25 million Series D equity financing round to fund the clinical trial of its ProSpace balloon spacer for prostate cancer treatment. The spacer helps reduce radiation therapy risks by pushing the prostate away from the rectum. The funds will also be used for technology platform expansion. BioProtects future pipeline includes applications for cervical cancer radiation therapy, pancreas radiation, and general surgery. The company aims to complete the pivotal study, gain FDA approval, and accelerate development of the next indication to its platform. The financing will support radiation oncology providers in shortening treatment cycles without compromising safety and cancer control.
InvestmentExpand
growth-positive
Israeli spacer balloon co BioProtect raises $13m
BioProtect, an Israeli bio-absorbable polymer spacer balloons developer, has announced the initial closing of a $13 million Series D equity financing round. The funding will be used to finance the ongoing multicenter FDA clinical trial of BioProtects lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy. The funds will also support the expansion of the technology platform. The financing round was led by the family office of Vincent Tchenguiz, with participation from Accelmed Ventures and KB Investments.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $62.25M |
| Last funding | Undisclosed |
| Stage | D |
| Rounds | 10 |
| Investors | 19 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | bioprotect.com |
Locations
Tsor St 8, Kokhav Ya'ir Tzur Yigal, Israel
Photos & Videos
2 item(s)
BioProtect Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Materials & SubstancesPolymersImplantsTags (12)
cancersurgerybiodegradableoncologyminimally-invasivemedical-devicesdoctorshospitalsmedical-technologiestreatmentspolymersradiologyGeographic Markets
EuropeUnited StatesBioProtect Financials
$62.25M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
D
Funding stage
10
Total rounds
19
Investors
Cumulative Funding Raised Over Time ($)
$4.0MApr 2017
$6.9MDec 2012
$7.6MFeb 2006
$8.6MJun 2008
$9.1MJun 2016
$9.1MMay 2025
$9.2MOct 2004
$34.2MSep 2020
$62.2MSep 2023
Private Equity Funding
Undisclosed Round
May 2025
Undisclosed
Peregrine Ventures
Undisclosed Round
Sep 2023
$28M
MVM Life Science Partners (Lead)
,
KB Investment, Almeda Ventures, Consensus Business Group (CBG), Peregrine Ventures, Triventures
D Round
Sep 2020
$25M
Almeda Ventures, Medtronic, Triventures, Accelmed, Peregrine Ventures, KB Investment, Vincent Tchenguiz
C Round
Apr 2017
$4M
BKP Med-Invest, Xenia Venture Capital
B Round
Jun 2016
$500K
AJJS Holdings Inc., Aran Research and Development Ltd., Rafi Gidron, EarlyCap, Xenia Venture Capital, Igal Ahouvi, Virginia Life Sciences Investments (VLSI) , Tevel Global Angels Inc
A Round
Dec 2012
$2.9M
Igal Ahouvi, Tevel Global Angels Inc, Xenia Venture Capital, Virginia Life Sciences Investments (VLSI) , AJJS Holdings Inc., Rafi Gidron
A Round
Jun 2008
$990.15K
Igal Ahouvi, Xenia Venture Capital, Rafi Gidron, EarlyCap
A Round
Feb 2006
$700K
Rafi Gidron, AJJS Holdings Inc., Igal Ahouvi, Xenia Venture Capital, EarlyCap, Shlomo Mashiach
Seed
Oct 2004
$150K
Xenia Venture Capital
Non-Equity Funding
GrantEvent
Oct 2014
$8K
Office of the Chief Scientist
BioProtect Lifecycle
Cumulative Funding Raised Over Time
$4.0MApr 2017
$6.9MDec 2012
$7.6MFeb 2006
$8.6MJun 2008
$9.1MJun 2016
$9.1MMay 2025
$9.2MOct 2004
$34.2MSep 2020
$62.2MSep 2023
All Events
Undisclosed Round
May 2025
Undisclosed
Peregrine Ventures
Undisclosed Round
Sep 2023
$28M
MVM Life Science Partners (Lead)
,
KB Investment, Almeda Ventures, Consensus Business Group (CBG), Peregrine Ventures, Triventures
D Round
Sep 2020
$25M
Almeda Ventures, Medtronic, Triventures, Accelmed, Peregrine Ventures, KB Investment, Vincent Tchenguiz
C Round
Apr 2017
$4M
BKP Med-Invest, Xenia Venture Capital
B Round
Jun 2016
$500K
AJJS Holdings Inc., Aran Research and Development Ltd., Rafi Gidron, EarlyCap, Xenia Venture Capital, Igal Ahouvi, Virginia Life Sciences Investments (VLSI) , Tevel Global Angels Inc
A Round
Dec 2012
$2.9M
Igal Ahouvi, Tevel Global Angels Inc, Xenia Venture Capital, Virginia Life Sciences Investments (VLSI) , AJJS Holdings Inc., Rafi Gidron
A Round
Jun 2008
$990.15K
Igal Ahouvi, Xenia Venture Capital, Rafi Gidron, EarlyCap
A Round
Feb 2006
$700K
Rafi Gidron, AJJS Holdings Inc., Igal Ahouvi, Xenia Venture Capital, EarlyCap, Shlomo Mashiach
Seed
Oct 2004
$150K
Xenia Venture Capital
GrantEvent
Oct 2014
$8K
Office of the Chief Scientist
BioProtect News
9 articles
growth-positive
Israeli balloon implant co BioProtect raises $28m
Israeli balloon implant company BioProtect has completed a $28 million financing round led by MVM Partners, with participation from current investors. The funds will be used for US commercialization of the BioProtect Balloon Implant System, which recently received FDA clearance for rectal protection during radiation therapy for prostate cancer. The companys CEO, Itay Barnea, expressed his belief in the potential of their product to revolutionize rectal protection from radiation toxicity during prostate cancer radiation therapy.
InvestmentExpand
growth-positive
Is it time to reconsider PSA tests for Prostate Cancer? | CTech
The article discusses the debate surrounding prostate cancer screening and treatment. It highlights the importance of personalized, patient-centered approaches and the potential side effects of invasive treatments. The CEO of BioProtect, Itay Barnea, emphasizes the need for a comprehensive evaluation of each patients unique factors. The global market for prostate cancer therapeutics is predicted to exceed $24.9 billion by 2030, driven by increasing cases and technological advancements in oncology. BioProtect produces biodegradable balloons for safe radiation therapy.
CustomersInvestment
growth-positive
BioProtect Notes Completion of Patient Enrollment for its IDE Pivotal Study of the ProSpace™ Balloon Spacer
BioProtect Ltd. has successfully enrolled all planned patients in the ongoing IDE ProSpace™ trial for its ProSpace™ Balloon Spacer. The trial aims to assess the safety and efficacy of the device in prostate cancer patients undergoing radiotherapy. The company expressed gratitude for the completion of the enrollment phase despite the challenges posed by the COVID-19 pandemic. BioProtects vision is to provide safer and improved clinical outcomes for patients undergoing radiation therapy. Last year, the company raised $25 million in funding from a group of international investors. The ProSpace™ Balloon Spacer is BioProtects first commercially available product, designed to reduce the radiation dose delivered to the anterior rectum by spacing it away from the prostate.
Investment
growth-positive
Prostate cancer protection co BioProtect raises $25m
Israeli startup BioProtect has closed a $25 million Series D equity financing round to fund the clinical trial of its ProSpace balloon spacer for prostate cancer treatment. The spacer helps reduce radiation therapy risks by pushing the prostate away from the rectum. The funds will also be used for technology platform expansion. BioProtects future pipeline includes applications for cervical cancer radiation therapy, pancreas radiation, and general surgery. The company aims to complete the pivotal study, gain FDA approval, and accelerate development of the next indication to its platform. The financing will support radiation oncology providers in shortening treatment cycles without compromising safety and cancer control.
InvestmentExpand
growth-positive
Israeli spacer balloon co BioProtect raises $13m
BioProtect, an Israeli bio-absorbable polymer spacer balloons developer, has announced the initial closing of a $13 million Series D equity financing round. The funding will be used to finance the ongoing multicenter FDA clinical trial of BioProtects lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy. The funds will also support the expansion of the technology platform. The financing round was led by the family office of Vincent Tchenguiz, with participation from Accelmed Ventures and KB Investments.
Investment
growth-positive
Vincent Tchenguiz to invest $7m in BioProtect
UK billionaire Vincent Tchenguiz will invest $7 million in BioProtect, a company that has developed a product for protecting healthy tissue against radiotherapy for the treatment of prostate cancer. The investment will help BioProtect complete clinical trials for marketing in the US. BioProtects product, a polymer balloon, is already being marketed in Europe and has potential applications for other types of cancer treatment. Xenia Venture Capital, a technology incubator, holds a 12% stake in BioProtect. Former Dune Medical senior executive Gil Rosen has been appointed CEO of BioProtect.
InvestmentExpand
New Data Presented at ESTRO 2018 Supports use of Balloon Spacers
growth-positive
FDA has granted investigational Device Exemption approval (IDE) to BioProtect
The Indian Bio & Health Sciences Industry awards, known as the BioSpectrum Excellence Awards, were recently given away at the Annual Gala Awards Nite on June 30, 2023. The awards honor the achievements of leaders in the industry. The event is highly anticipated in the industry.
None
growth-positive
Balloon implant co BioProtect raises $3.5m
Xenia Venture Capital portfolio company BioProtect has raised $3.5 million at a company value of $20 million. BioProtect has developed a minimally invasive balloon implant to reduce rectal toxicity in prostate cancer radiation therapy. The financing round is expected to raise the value of Xenias assets by NIS 4.4 million. BioProtects technological platform can be adapted to other medical applications and procedures. The product has been proven safe and effective in treating various medical problems.
Investment
BioProtect Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 98 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
BioProtect Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 513591396 |
| Crunchbase | bioprotect |
| Phone | +97297731929 |
| Creator | Tamar Weiss |
| Creator email | tamar.e.weiss@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-09-27T00:00:00.000Z |
| Created | 2014-07-20T00:00:00.000Z |